IP Library › Granted Patent US 12673033
Granted Patent B2
US 12673033 · App. 18/754,044 · Granted Jul 7, 2026

Multiple myeloma treatment

Inventors: Mihael H. Polymeropoulos (Potomac, MD); Louis William Licamele (Potomac, MD); Christian Lavedan (Potomac, MD)
Assignee: Vanda Pharmaceuticals Inc.
A61K31/165A61K9/0019A61K9/0053A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12673033
App. No.
18/754,044
Granted
Jul 7, 2026
Kind
B2
Abstract

The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).

Claims (21)

1 . A method of treating a patient suffering from multiple myeloma (MM), the method consisting essentially of:

administering to the patient an amount of trichostatin A (TSA) effective to decrease expression of at least one gene in the patient, the at least one gene being selected from a group consisting of: CCNB1, AURKB, CDC2, KIF11, KIF2C, TOP2A, ASPM, CKS1B, and WEE1.

2 . The method of claim 1 , wherein the amount of TSA is effective to decrease expression of either or both of CCNB1 and AURKB in the patient.

3 . The method of claim 1 , wherein the amount of TSA is effective to decrease expression of either or both of CKS1B and WEE1.

4 . The method of claim 1 , wherein the amount of TSA is effective to decrease expression of each of CCNB1, AURKB, CDC2, KIF11, KIF2C, TOP2A, ASPM, CKS1B, and WEE1.

5 . The method of claim 1 , wherein the amount of TSA is between about 0.01 mg/kg/day and about 100 mg/kg/day.

6 . The method of claim 1 , wherein the amount of TSA is between about 0.1 mg/kg/day and about 10 mg/kg/day.

7 . The method of claim 6 , wherein the amount of TSA is between about 0.5 mg/kg/day and about 5 mg/kg/day.

8 . The method of claim 1 , wherein administering includes orally administering.

9 . The method of claim 1 , wherein administering includes intravenously administering.

10 . A method of treating a patient suffering from multiple myeloma (MM), the method consisting essentially of:

determining, from a biological sample obtained from the spatient's body, a level of expression of one or more gene in the patient, the one or more gene selected from a group consisting of: CCNB1, AURKB, CDC2, KIF11, KIF2C, TOP2A, ASPM, CKS1B, and WEE1; and

in the case that the level of expression of the one or more gene is indicative of overexpression, as compared to an individual not suffering from MM, administering to the patient an amount of trichostatin A (TSA) effective to decrease expression of the one or more gene.

11 . The method of claim 10 , wherein the effective amount is an amount sufficient to decrease expression of either or both of CCNB1 and AURKB in the patient.

12 . The method of claim 10 , wherein the effective amount is an amount sufficient to decrease expression of either or both of CKS1B and WEE1.

13 . The method of claim 10 , wherein the effective amount is an amount sufficient to decrease expression of each of CCNB1, AURKB, CDC2, KIF11, KIF2C, TOP2A, ASPM, CKS1B, and WEE1.

14 . The method of claim 10 , wherein the amount of TSA is between about 0.01 mg/kg/day and about 100 mg/kg/day.

15 . The method of claim 14 , wherein the amount of TSA is between about 0.1 mg/kg/day and about 10 mg/kg/day.

16 . The method of claim 15 , wherein the amount of TSA is between about 0.5 mg/kg/day and about 5 mg/kg/day.

17 . The method of claim 10 , wherein administering includes orally administering.

18 . The method of claim 10 , wherein administering includes intravenously administering.